Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Ctd Holdings Inc (CTDH)

Ctd Holdings Inc (CTDH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 14,619
  • Shares Outstanding, K 169,983
  • Annual Sales, $ 1,010 K
  • Annual Income, $ -7,530 K
  • 60-Month Beta -0.89
  • Price/Sales 10.63
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CTDH with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.04
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 12/10/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0340 +152.94%
on 11/19/20
0.1400 -38.57%
on 11/09/20
-0.0420 (-32.81%)
since 11/06/20
3-Month
0.0340 +152.94%
on 11/19/20
0.1900 -54.74%
on 09/14/20
-0.0740 (-46.25%)
since 09/08/20
52-Week
0.0340 +152.94%
on 11/19/20
0.3499 -75.42%
on 01/03/20
-0.1440 (-62.61%)
since 12/06/19

Most Recent Stories

More News
Cyclo Therapeutics Announces Two Presentations at WORLDSymposium2021

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company developing a cyclodextrin platform for the treatment of Neurodegenerative Diseases, including their lead candidate (Trappsol...

CTDH : 0.0860 (+36.51%)
Cyclo Therapeutics Phase 3 Pivotal Program Can Begin Enrollment Per US FDA

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company developing a cyclodextrin platform for the treatment of Neurodegenerative Diseases, including their lead candidate (Trappsol...

CTDH : 0.0860 (+36.51%)
Cyclo Therapeutics to Present at 2020 Annual Conference for NPC Patients, Families, and Health Professionals in the United Kingdom

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease,...

CTDH : 0.0860 (+36.51%)
Cyclo Therapeutics Inc. Announces Additional Efficacy Data from its Ongoing Phase I/II Trial using Trappsol® CycloTM Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1)

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease,...

CTDH : 0.0860 (+36.51%)
Cyclo Therapeutics Closes $2.8 Million Private Placement Led by Novit LP With $1.0 Million

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease,...

CTDH : 0.0860 (+36.51%)
Cyclo Therapeutics Announces Presentations on Phase I and Phase I/II Trials using Trappsol® Cyclo™ Intravenously to Treat Patients with Niemann-Pick Disease Type C1 at National Niemann Pick Disease Foundation Family Support and Medical Conference

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C1 (NPC1) and Alzheimer’s Disease,...

CTDH : 0.0860 (+36.51%)
Cyclo Therapeutics Reports on Eighteen Month Expanded Access Program in Single Alzheimer’s Patient

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease,...

CTDH : 0.0860 (+36.51%)
Cyclo Therapeutics’ Clinical Data Webinar Recording Available on Company Website

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease,...

CTDH : 0.0860 (+36.51%)
Cyclo Therapeutics Inc. Announces Positive Top Line Results from Phase I Trial and Interim Analysis of Phase I/II Trial using Trappsol® Cyclo™ Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1)

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C1 (NPC1) and Alzheimer’s Disease,...

CTDH : 0.0860 (+36.51%)
Cyclo Therapeutics to Hold Call for Patients and Investors Wednesday, May 20 at 4:30 pm EDT

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease,...

CTDH : 0.0860 (+36.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cyclo Therapeutics Inc. is a clinical-stage biotechnology company. It develops cyclodextrin-based products for the treatment of disease. The company's Trappsol(R) Cyclo(TM), an orphan drug designated product primarily in the United States and Europe, is in ongoing formal clinical trials for Niemann-Pick...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 0.1186
1st Resistance Point 0.1023
Last Price 0.0860
1st Support Level 0.0664
2nd Support Level 0.0468
3rd Support Level N/A

See More

52-Week High 0.3499
Fibonacci 61.8% 0.2292
Fibonacci 50% 0.1920
Fibonacci 38.2% 0.1547
Last Price 0.0860
52-Week Low 0.0340

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar